|Bid||248.37 x 1200|
|Ask||248.42 x 800|
|Day's Range||247.40 - 252.82|
|52 Week Range||208.07 - 287.94|
|Beta (3Y Monthly)||0.76|
|PE Ratio (TTM)||19.29|
|Earnings Date||Jul 18, 2019|
|Forward Dividend & Yield||4.32 (1.73%)|
|1y Target Est||286.87|
The Federal Trade Commission has cleared UnitedHealth Group’s $4.3 billion purchase of a large physician group from DaVita, bringing hundreds of clinics and dozens of urgent-care centers under its umbrella.
UnitedHealth Group Inc. has completed its $4.3 billion acquisition of the physician group of DaVita Inc.
Colorado’s attorney general has filed a complaint — and reached a settlement — regarding the proposed merger of physicians groups owned by DaVita Inc. (NYSE: DVA) and UnitedHealth Group (NYSE: UNH) to curtail any decrease of competition that could come with the joining of the two businesses. The complaint was filed to ensure Colorado would get protections for residents in Colorado Springs that would be most affected by the merger. The moves come ahead of a vote from the U.S. Federal Trade Commission that approved the $4.3 billion merger of DaVita Medical Group, a subsidiary of DaVita, and Optum, owned by insurance giant UnitedHealth Group.
Optum, a leading health services company, completed its acquisition of DaVita Medical Group, one of the nation’s leading independent medical groups, from DaVita Inc. (DVA). As part of the transaction, HealthCare Partners Nevada, DaVita Medical Group’s primary care practice in southern Nevada, will become part of Intermountain Healthcare. DaVita Medical Group joins OptumCare, which serves more than 80 health plans, and will provide quality care to a combined 16 million patients.
The Federal Trade Commission said late Wednesday UnitedHealth Group Inc. and DaVita Inc. have agreed to a settlement to resolve FTC allegations their $4.3 billion deal would stifle competition in the Las Vegas area. Under the proposed settlement, UnitedHealth would have 40 days to sell DaVita's healthcare provider in the Las Vegas region, known as HealthCare Partners of Nevada, to Intermountain Healthcare, a Utah-based healthcare provider and insurer. The acquisition was first announced in December 2017. UnitedHealth stock rose 0.6% and DaVita shares fell 0.1% in the extended session after ending the regular trading day up 1.8% and 3.1%.
As was expected, the Federal Reserve left interest rates unchanged following the conclusion of its two-day meeting today. But what market participants wanted was inklings of hope that a rate cut could materialize later this year. That wish was granted, helping stocks rally into the close.Source: Shutterstock Importantly, the word "patient" was not featured in the Federal Open Market Committee (FOMC) statement, indicating the Fed could take a more proactive approach to managing rates if the world's largest economy starts to show signs of weakness."The Committee continues to view sustained expansion of economic activity, strong labor market conditions, and inflation near the Committee's symmetric 2 percent objective as the most likely outcomes, but uncertainties about this outlook have increased," said the FOMC. "In light of these uncertainties and muted inflation pressures, the Committee will closely monitor the implications of incoming information for the economic outlook and will act as appropriate to sustain the expansion, with a strong labor market and inflation near its symmetric 2 percent objective."InvestorPlace - Stock Market News, Stock Advice & Trading TipsOne Fed member, James Bullard, preferred to lower rates by 25 basis points at this meeting. That was not enough to deliver the coveted rate cut, but it was enough to send the Nasdaq Composite and the S&P 500 higher by 0.42% and 0.3%. The Dow Jones Industrial Average gained 0.15%. Winners, But Were There Enough?Yes, the Dow is home to just 30 stocks and in late trading, two-thirds of those names were higher. But if nitpicking is to occur on an otherwise positive day, it is worth noting that Dow's offenders today were all cyclical names. Going a bit further with the scrutiny, several of the Dow losers today were among the index's biggest components. But to be fair, some of these stocks have been on winning streaks and the Wednesday losses were mostly modest. * 7 Value Stocks to Buy for the Second Half UnitedHealth Group (NYSE:UNH), the Dow Jones' largest healthcare component, was the blue-chip index's biggest winner today, adding 1.82%. Not to play politics here, but UNH's Wednesday rally occurred a day after President Donald Trump kicked off his reelection at a rally in Orlando.Obviously, the election is a long way out, but as has been note here, UNH and rival healthcare providers have been under pressure amid speculation that Medicare For All could become a reality if a Democrat wins the White House. Again, November 2020 is a long way away, but UNH has been trending higher for almost two months and looks poised to wipe out its year-to-date loss.American Express (NYSE:AXP) was one of the best-performing financial services names in the Dow today. The stock, a Warren Buffett favorite, added 1.01% after Bank of America Merrill Lynch analyst Jason Kupferberg put a "buy" rating and a $145 price target on the shares, implying significant upside from Wednesday's close.AXP is a "a worthy investment which offers customers unique experiences beyond traditional rewards points" and "we have been pleasantly surprised to see [American Express] strategically raise card fees to help offset these costs," said the analyst in a note cited by Barron's.Home improvement giant Home Depot (NYSE:HD) ticked higher, aided by the Fed minutes. Lower interest rates often benefit companies with exposure to the residential real estate market, and that rate chatter could aid Home Depot in its quest to break through resistance at the $210 area. If that happens, it could be off to the races for the stock. Bottom Line on the Dow Jones TodayIt is difficult to complain about Wednesday's price action. Sure, stocks could have gained more, but for the most part, investors got what they wanted in terms of dovish Fed commentary. Plus, Fed funds futures are indicating a July rate cut is a real possibility.Fortunately, investors looking to prepare for a rate cut without incurring significantly higher risk can turned to a beloved asset class: dividend stocks and ETFs. Several dividend ETFs hit record highs today and a large batch are withing just a few percentage points of doing the same.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post Dow Jones Today: Stocks Almost Had Some Fed Fun appeared first on InvestorPlace.
The Dow Jones and other key stock market indexes showed modest gains after the Fed left interest rates unchanged but said it's ready to act.
CVS Health (NYSE: CVS) faces two distinct headwinds that are putting pressure on CVS stock.First, markets are cautious over the drug store and drug manufacturing market as the government pressure all players to lower drug prices.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDoubts over CVS' acquisition of Aetna are adding more distractions for management in the near-term. With CVS stock testing the $51.72 yearly low on at least five occasions since March, what will it take for the stock to rebound?CVS reported first-quarter earnings of $1.62 and also raised its full-year adjusted EPS guidance to $6.75 to $6.90. This is up from the previous guidance of $6.68 to $6.88 a share.The Q1 beat and improved outlook are due largely to the inclusion of managed care operations. The company also included revenue from SilverScript Medicare Part D, which contributed $17.9 billion of revenue for the quarter. * 5 Stocks to Buy for $20 or Less Better synergies with Aetna also contributed favorably to the higher outlook. CVS expects it will exceed its target savings of $750 million in 2020. It found synergies stemming from the elimination of duplication in corporate and operational functions, medical cost savings such as formulary alignment, and purchasing efficiencies. By 2022, CVS forecast saving $1.5 billion to $2 billion, well above its deal synergy targets.CVS forecast cash flow of between $9.8 billion and $10.3 billion and will use $4.2 billion to $4.6 billion to pay down its debt. Its debt/equity of 1.25 times is above that of Cigna Corporation (NYSE: CI) at 0.95, and UnitedHealth (NYSE: UNH) at 0.74, both of which are attractive investments.Despite the less favorable debt/equity, CVS Health pays a dividend yielding 3.69%. Walgreens Boots Alliance (NASDAQ: WBA) also has a lower debt/equity of 0.73 but its dividend is slightly lower too, at 3.35%. Value Investing OpportunityInvestors who think that CVS has deep value with a forward P/E of 7.6 times are betting the company will mitigate near-term headwinds hurting the business. In Q1, prescription growth of 5.5% benefited from the support of clinical care programs and network relationships.The company will improve margins in its long-term care business. And with PBM, the idea of a net cost pricing model is resonating with clients. Some clients will adapt to this offering while CVS expects its uptake improving in 2020 and beyond.CVS is testing new approaches in delivering and managing health care. Its Houston HealthHub stores bring health care services into communities. Meeting people where they are should drum up more business.Still, CVS will primarily use data and analytics to deliver such services at the best cost. Plus, it has a long-term vision of seamlessly connecting consumer experiences across digital and clinical interactions.Initial results from the Houston stores are encouraging. The locations are performing better than expected, giving the company the green light to expand the HealthHUB model. RisksAlthough CVS Health's market share stood at 26.2% in the first quarter, front store comparable sales rose just 0.4%. Adjusted operating income from Retail/Long-term care dropped 18.9%. Reimbursement pressure, higher legal costs, and higher expenses weighed on Q1 results.Should costs grow higher than expected in the course of this year, CVS may lower its guidance. Fortunately, synergies from the Aetna acquisition are tracking higher than the company expected. HealthHUB is resonating well with customers. This is encouraging the company to add more net new items in the front-store of the self-care and wellness areas. Along with expanding MinuteClinic services, CVS will continue expanding the interactions between pharmacists and patients who need it most. ValuationThe 14 analysts offering a price target on CVS stock have an average price of $70.18, which is ~30% above the recent closing price of $54.17. Conversely, investors could assume a perpetuity growth rate of between 5% and 6% in the 5Y DCF Growth Exit model. In this scenario, the fair value of CVS stock is $63 a share, implying an upside of 16% for investors (per finbox.io). Your CVS Stock TakeawayThe CVS and Aetna deal is getting challenged. Investors could bet that the court lets the deal close. More importantly, CVS is already reaping the benefits of the combination by cutting costs. By delivering better services to the customers it services, the company will keep growing.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities.Compare Brokers The post CVS Stock Has More Going for It Than Just a 3.69% Dividend Yield appeared first on InvestorPlace.
UnitedHealth Group will release its second quarter 2019 financial results on Thursday, July 18, 2019, before the market opens, and will host a teleconference at 8:45 a.m.
UnitedHealth Group (UNH) closed at $245.80 in the latest trading session, marking a +0.18% move from the prior day.
If you want to know who really controls UnitedHealth Group Incorporated (NYSE:UNH), then you'll have to look at the...
Southwest Station is the end of the line for the Metro Green Line extension scheduled to open in 2023, but it’s just the beginning for a new Business Journal series exploring the areas surrounding each of 16 new light rail stations.
Senior Judge Richard Leon sent shares in drug store chain CVS (NYSE:CVS) lower after saying he might try to stop its $69 billion merger with Aetna (NYSE:AET), a health insurer. CVS announced the deal in December 2017. Since then, CVS stock is down over 25%. It was due to open for trade June 12 at about $54 per share. CVS' market cap of $70 billion is now just 36% of its 2018 revenue, which was $194 billion.Source: Mike Mozart via FlickrLeon told CVS' and Aetna's lawyers to "cancel their summer vacation," arguing the Department of Justice barely considered what adding 21 million customers could do for CVS' Caremark, a Pharmacy Benefit Manager (PBM).Oral arguments will be held July 17, a ruling coming shortly after. CVS has already agreed to sell its Medicare Part D plan, the only overlap with Aetna, to Wellcare, which in turn is being bought by Centene (NYSE:CNC).InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Question of CostsCentene's involvement begs the main question raised by the merger, which is whether the deal can cut healthcare costs.Centene's market advantage is cost visibility. Its business model is to profit in Medicare and Medicaid by owning clinics and other facilities its covered patients use. It was a big winner on the Obamacare exchanges, where it could offer much lower prices than standard insurance plans.The American Hospital Association opposes the CVS-Aetna merger, while supporting mergers between hospital groups, arguing that hospitals aren't the cause of health care inflation. * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever They're right. Drugs are. Combining PBMs and insurers is how the industry is fighting drug costs.CVS plans to turn 1,500 stores into "HealthHubs," after the merger, with labs, nurses and dieticians to treat chronic conditions like diabetes, representing 75% of America's health care bill.CVS has been preparing itself for a favorable outcome since February, when it reached the agreement with the Department of Justice Judge Leon is now reviewing. The Question of CompetitionLeon's objections are centered on Caremark, but that unit's problems were behind the merger in the first place.The PBM model was upended four years ago when UnitedHealth Group (NYSE:UNH), the largest private insurer, bought Catamaran, another PBM, for its own OptumRx unit.The deal made the stand-alone PBM market untenable. Since then, Express Scripts, the largest PBM, was acquired by Cigna (NYSE:CI), an Aetna rival. That merger, and the CVS-Aetna tie-up, followed failed attempts by Aetna to merge with Humana (NYSE:HUM) and by Cigna to merger with Anthem (NASDAQ:ANTM). Having failed at horizontal mergers because of their size (despite UnitedHealth being bigger than either combination), the second-tier players moved toward vertical mergers, hoping to compete through cost control.Thus, Leon seems intent on stopping a train that has already left the station. UnitedHealth, Centene and Cigna own PBMs, and he's going to stop CVS-Aetna because CVS owns one? The Bottom Line on CVS StockNot all mergers work. CVS' own acquisition of Omnicare, a long-term care provider, caused it take a $3.9 billion write-down in the second quarter of last year, and a net loss for all of 2018. * 7 U.S. Stocks to Buy With Limited Trade War Exposure But given how far insurers have gone along the road to matching income with outgo, the Aetna merger was looking like a winner. The delays have pushed CVS shares down enough to give its 50 cent per share dividend a yield of 3.82%, even though absent of write-offs, it covers that dividend with earnings two to three times over each year.The Leon delay looks like a good opportunity for income investors to grab a bargain.Dana Blankenhorn is a financial and technology journalist. He is the author of the mystery thriller, The Reluctant Detective Finds Her Family, available at the Amazon Kindle store. Write him at firstname.lastname@example.org or follow him on Twitter at @danablankenhorn. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Quality Cheap Stocks to Buy With $10 * 7 U.S. Stocks to Buy With Limited Trade War Exposure * 6 Growth Stocks That Could Be the Next Big Thing Compare Brokers The post Can CVS Stock Overcome the Latest Wrench in Its Aetna Merger? appeared first on InvestorPlace.
Banking on a rising top line and health service business, UnitedHealth (UNH) holds great promise to garner benefits for investors.
UnitedHealth Group Inc NYSE:UNHView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for UNH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting UNH. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding UNH totaled $78.45 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. UNH credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
“Medicare for All” got a hearing Wednesday before a powerful House panel, but there continued to be signs that top Democrats aren’t embracing the issue.
The National Committee for Quality Assurance has recognized UnitedHealthcare Community Plan of Tennessee with two awards – Distinction in Multicultural Health Care and Distinction in Long-Term Services and Supports .
Advisory Board's Annual Health Care Survey shows executives’ top priorities include improving ambulatory care access, population health and risk contracting
On CNBC's "Fast Money," Mark Tepper said he likes salesforce.com, inc. (NYSE: CRM ). It had a blow-out quarter, but the stock hasn't reacted as positively as it should have. Tepper also likes ...
UnitedHealth Group (UNH) closed at $245.92 in the latest trading session, marking a -0.89% move from the prior day.